nach oben

Medical Oncology

Erschienen in:

01.05.2023 | Original Paper

JMJD5 inhibits lung cancer progression by regulating glucose metabolism through the p53/TIGAR pathway

verfasst von: Guiling Liu, Hongyan Qi, Jing Shen

Erschienen in: Medical Oncology | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Metabolic reprogramming is considered one of the main driving forces for tumor progression, providing energy and substrates of biosynthesis to support rapid neoplastic proliferation. Particularly, the tumor suppressor protein p53 was shown to revert the Warburg effect and play complex roles in regulating glucose metabolism. Jumonji C domain-containing protein 5 (JMJD5) has previously been reported as a negative regulator of p53. However, the role of JMJD5 in p53-mediated metabolic reprogramming remains elusive. Here, we discovered that knockdown of JMJD5 significantly enhances TIGAR expression in p53 wild-type non-small cell lung cancer (NSCLC) cells, which could further suppress glycolysis and promote the pentose phosphate pathway. Besides, JMJD5 knockdown promotes the NSCLC cell proliferation in vitro and xenograft tumor growth in vivo, while silencing TIGAR can abolish this effect. Low JMJD5 expression levels are associated with elevated TIGAR levels and correlates with poor prognosis in lung cancer patients. Taken together, our findings suggest that JMJD5 is a key regulator of tumor glucose metabolism by targeting the p53/TIGAR metabolic pathway.

Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. https://doi.org/10.1158/2159-8290.CD-21-1059.CrossRefPubMed

Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–14. https://doi.org/10.1126/science.123.3191.309.CrossRefPubMed

Gomes AS, et al. p53 and glucose metabolism: an orchestra to be directed in cancer therapy. Pharmacol Res. 2018;131:75–86. https://doi.org/10.1016/j.phrs.2018.03.015.CrossRefPubMed

Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014;39(8):347–54. https://doi.org/10.1016/j.tibs.2014.06.005.CrossRefPubMedPubMedCentral

Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative Stress in Cancer. Cancer Cell. 2020;38(2):167–97. https://doi.org/10.1016/j.ccell.2020.06.001.CrossRefPubMedPubMedCentral

Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137(3):413–31. https://doi.org/10.1016/j.cell.2009.04.037.CrossRefPubMed

Mello SS, Attardi LD. Deciphering p53 signaling in tumor suppression. Curr Opin Cell Biol. 2018;51:65–72. https://doi.org/10.1016/j.ceb.2017.11.005.CrossRefPubMed

Liu J, et al. Tumor suppressor p53 and metabolism. J Mol Cell Biol. 2019;11(4):284–92. https://doi.org/10.1093/jmcb/mjy070.CrossRefPubMed

Liu Y, Gu W. The complexity of p53-mediated metabolic regulation in tumor suppression. Semin Cancer Biol. 2022;85:4–32. https://doi.org/10.1016/j.semcancer.2021.03.010.CrossRefPubMed

10.

Oh S, Janknecht R. Histone demethylase JMJD5 is essential for embryonic development. Biochem Biophys Res Commun. 2012;420(1):61–5. https://doi.org/10.1016/j.bbrc.2012.02.115.CrossRefPubMed

11.

Ishimura A, et al. Jmjd5, an H3K36me2 histone demethylase, modulates embryonic cell proliferation through the regulation of Cdkn1a expression. Development. 2012;139(4):749–59. https://doi.org/10.1242/dev.074138.CrossRefPubMed

12.

Zhu H, Hu S, Baker J. JMJD5 regulates cell cycle and pluripotency in human embryonic stem cells. Stem Cells. 2014;32(8):2098–110. https://doi.org/10.1002/stem.1724.CrossRefPubMed

13.

Youn MY, et al. JMJD5, a Jumonji C (JmjC) domain-containing protein, negatively regulates osteoclastogenesis by facilitating NFATc1 protein degradation. J Biol Chem. 2012;287(16):12994–3004. https://doi.org/10.1074/jbc.M111.323105.CrossRefPubMedPubMedCentral

14.

Jones MA, et al. Jumonji domain protein JMJD5 functions in both the plant and human circadian systems. Proc Natl Acad Sci U S A. 2010;107(50):21623–8. https://doi.org/10.1073/pnas.1014204108.CrossRefPubMedPubMedCentral

15.

Saran AR, et al. JMJD5 links CRY1 function and proteasomal degradation. PLoS Biol. 2018;16(11):e2006145. https://doi.org/10.1371/journal.pbio.2006145.CrossRefPubMedPubMedCentral

16.

Zhao Z, et al. Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer. Int J Clin Exp Pathol. 2015;8(9):10325–34.PubMedPubMedCentral

17.

Wang HJ, et al. JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1alpha-mediated glucose metabolism. Proc Natl Acad Sci U S A. 2014;111(1):279–84. https://doi.org/10.1073/pnas.1311249111.CrossRefPubMed

18.

Wang HJ, et al. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. Oncogene. 2019;38(1):17–32. https://doi.org/10.1038/s41388-018-0414-x.CrossRefPubMed

19.

Zhang R, et al. JMJD5 is a potential oncogene for colon carcinogenesis. Int J Clin Exp Pathol. 2015;8(6):6482–9.PubMedPubMedCentral

20.

Yao Y, Zhou WY, He RX. Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53/NF-kappaB pathway. Biomed Pharmacother. 2019;109:1994–2004. https://doi.org/10.1016/j.biopha.2018.07.144.CrossRefPubMed

21.

Song J, et al. A novel protein encoded by ZCRB1-induced circHEATR5B suppresses aerobic glycolysis of GBM through phosphorylation of JMJD5. J Exp Clin Cancer Res. 2022;41(1):171. https://doi.org/10.1186/s13046-022-02374-6.CrossRefPubMedPubMedCentral

22.

Qu LH, et al. Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma. Cancer Immunol Immunother. 2022;71(10):2449–67. https://doi.org/10.1007/s00262-022-03167-8.CrossRefPubMed

23.

Wang Z, et al. Differential proteome profiling of pleural effusions from lung cancer and benign inflammatory disease patients. Biochim Biophys Acta. 2012;1824(4):692–700. https://doi.org/10.1016/j.bbapap.2012.01.016.CrossRefPubMed

24.

Oh S, Shin S, Janknecht R. The small members of the JMJD protein family: enzymatic jewels or jinxes? Biochim Biophys Acta Rev Cancer. 2019;1871(2):406–18. https://doi.org/10.1016/j.bbcan.2019.04.002.CrossRefPubMedPubMedCentral

25.

Wang H, et al. Jumonji-C domain-containing protein 5 suppresses proliferation and aerobic glycolysis in pancreatic cancer cells in a c-Myc-dependent manner. Cell Signal. 2022;93:110282. https://doi.org/10.1016/j.cellsig.2022.110282.CrossRefPubMed

26.

Huang X, et al. JMJD5 interacts with p53 and negatively regulates p53 function in control of cell cycle and proliferation. Biochim Biophys Acta. 2015;1853(10 pt A):2286–95. https://doi.org/10.1016/j.bbamcr.2015.05.026.CrossRefPubMed

27.

Bensaad K, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126(1):107–20. https://doi.org/10.1016/j.cell.2006.05.036.CrossRefPubMed

28.

Green DR, Chipuk JE. p53 and metabolism: inside the TIGAR. Cell. 2006;126(1):30–2. https://doi.org/10.1016/j.cell.2006.06.032.CrossRefPubMed

29.

Tang J, et al. Structure, regulation, and biological functions of TIGAR and its role in diseases. Acta Pharmacol Sin. 2021;42(10):1547–55. https://doi.org/10.1038/s41401-020-00588-y.CrossRefPubMedPubMedCentral

30.

Liu H, et al. Clipping of arginine-methylated histone tails by JMJD5 and JMJD7. Proc Natl Acad Sci U S A. 2017;114(37):E7717–26. https://doi.org/10.1073/pnas.1706831114.CrossRefPubMedPubMedCentral

31.

Shen J, et al. JMJD5 cleaves monomethylated histone H3 N-tail under DNA damaging stress. EMBO Rep. 2017;18(12):2131–43. https://doi.org/10.15252/embr.201743892.CrossRefPubMedPubMedCentral

32.

Wilkins SE, et al. JMJD5 is a human arginyl C-3 hydroxylase. Nat Commun. 2018;9(1):1180. https://doi.org/10.1038/s41467-018-03410-w.CrossRefPubMedPubMedCentral

33.

Berkers CR, et al. Metabolic regulation by p53 family members. Cell Metab. 2013;18(5):617–33. https://doi.org/10.1016/j.cmet.2013.06.019.CrossRefPubMedPubMedCentral

34.

Maddocks OD, et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature. 2013;493(7433):542–6. https://doi.org/10.1038/nature11743.CrossRefPubMed

35.

Cheung EC, Ludwig RL, Vousden KH. Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death. Proc Natl Acad Sci U S A. 2012;109(50):20491–6. https://doi.org/10.1073/pnas.1206530109.CrossRefPubMedPubMedCentral

36.

Geng J, et al. The diverse role of TIGAR in cellular homeostasis and cancer. Free Radic Res. 2018;52(11–12):1240–9. https://doi.org/10.1080/10715762.2018.1489133.CrossRefPubMed

37.

Li M, et al. A TIGAR-regulated metabolic pathway is critical for protection of brain ischemia. J Neurosci. 2014;34(22):7458–71. https://doi.org/10.1523/JNEUROSCI.4655-13.2014.CrossRefPubMedPubMedCentral

38.

Wang J, et al. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes. Cancer Lett. 2016;378(2):69–79. https://doi.org/10.1016/j.canlet.2016.05.004.CrossRefPubMedPubMedCentral

39.

Xie JM, et al. TIGAR has a dual role in cancer cell survival through regulating apoptosis and autophagy. Cancer Res. 2014;74(18):5127–38. https://doi.org/10.1158/0008-5472.CAN-13-3517.CrossRefPubMed

40.

Siegel RL, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.CrossRefPubMed

41.

Donehower LA, et al. Integrated analysis of TP53 gene and pathway alterations in the cancer genome Atlas. Cell Rep. 2019;28(5):1370-84 e5. https://doi.org/10.1016/j.celrep.2019.07.001.CrossRefPubMedPubMedCentral

Titel: JMJD5 inhibits lung cancer progression by regulating glucose metabolism through the p53/TIGAR pathway
verfasst von: Guiling Liu
Hongyan Qi
Jing Shen
Publikationsdatum: 01.05.2023
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 5/2023
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-023-02016-7

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

JMJD5 inhibits lung cancer progression by regulating glucose metabolism through the p53/TIGAR pathway

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2023

Myofascial pain syndrome in the oncologic patient: general considerations

Determination of Rutin's antitumoral effect on EAC solid tumor by AgNOR count and PI3K/AKT/mTOR signaling pathway

Zoledronic acid induces ferroptosis by upregulating POR in osteosarcoma

The impact of hypoxia on extracellular vesicle secretome profile of cancer

l-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia: a comprehensive review

Letter on “Role of gut microbiome in immune regulation and immune checkpoint therapy of colorectal cancer”

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie